Clinical Oncology
Volume 18, Issue 4 , Pages 338-344 , May 2006

Pilot Study of Preoperative Combined Modality Treatment for Locally Advanced Operable Oesophageal Carcinoma: Toxicities and Long-term Outcome

  • S. Mukherjee

      Affiliations

    • Velindre Hospital, Whitchurch, Cardiff, Wales, UK
    • ,
  • J. Abraham

      Affiliations

    • Velindre Hospital, Whitchurch, Cardiff, Wales, UK
    • ,
  • A. Brewster

      Affiliations

    • Velindre Hospital, Whitchurch, Cardiff, Wales, UK
    • ,
  • R. Hardwick

      Affiliations

    • University Hospital of Wales, Heath Park, Cardiff, Wales, UK
    • ,
  • T. Havard

      Affiliations

    • Royal Glamorgan Hospital, Llantrisant, Wales, UK
    • ,
  • W. Lewis

      Affiliations

    • Royal Gwent Hospital, Newport, Wales, UK
    • ,
  • C. Askill

      Affiliations

    • Singleton Hospital, Swansea, Wales, UK
    • ,
  • J. Manson

      Affiliations

    • Singleton Hospital, Swansea, Wales, UK
    • ,
  • G.T. Williams

      Affiliations

    • University Hospital of Wales, Heath Park, Cardiff, Wales, UK
    • ,
  • S.A. Roberts

      Affiliations

    • University Hospital of Wales, Heath Park, Cardiff, Wales, UK
    • ,
  • J. Court

      Affiliations

    • Velindre Hospital, Whitchurch, Cardiff, Wales, UK
    • ,
  • T. Crosby

      Affiliations

    • Velindre Hospital, Whitchurch, Cardiff, Wales, UK
    • Corresponding Author InformationAuthor for correspondence: Dr Tom Crosby, Velindre Hospital, Whitchurch, Cardiff CF14 2TL, Wales, UK. Tel: +44-2920316202; Fax: +44-2920316267.

Received 9 April 2005 ,Revised 18 October 2005 ,Accepted 15 December 2005.

References 

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8–31
  2. Pye JK, Crumlin MK, Charles J, Kerwat R, Foster ME, Biffin A. Hospital clinicians in Wales. One-year survey of carcinoma of the oesophagus and stomach in Wales. Br J Surg. 2001;88:278–285
  3. Blazeby J, Farndon J, Donovan J, Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer. 2000;88:1781–1787
  4. Medical Research Council (MRC) Oesophageal Cancer Working Group . Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727–1733
  5. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg. 2001;88:338–356
  6. Urschel JD, Vasan H. A meta-analysis of randomised controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185:538–543
  7. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86:1086–1091
  8. Polee MB, Tilanus HW, Eskens FA, et al. Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the oesophagus. Ann Oncol. 2003;14:1253–1257
  9. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 functions confers sensitisation to Taxol by increasing G2/M arrest and aoiotisus. Nat Med. 1996;2:72–79
  10. Mason KA, Milas L, Peters LI. Effect of paclitaxel (taxol) alone and in combination with radiation of the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys. 1995;32:1381–1389
  11. Toy EW, Crosby TD, Bowrey DJ, et al. Neoadjuvant chemoradiotherapy in carcinoma of the oesophagus. Br J Cancer. 1998;78(Suppl 2):Proc BOA 22(067)
  12. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979–1984
  13. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodality therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–467
  14. Bossett JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161–167
  15. Suntharalingam M, Moughan J, Coia LR, et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996–1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2003;56:981–987
  16. Wright CD, Wain JC, Lynch TJ, et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg. 1997;114:811–816
  17. Adelstein DJ, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol. 2000;18:2032–2039
  18. Schnirer II, Komaki R, Yao J, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001;24:91–95
  19. Ajani JA, Komaki R, Putnam JB, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001;92:279–286
  20. Safran H, Galssert H, Akerman P, et al. Paclitaxel, cisplatin and concurrent radiation for esophageal cancer. Cancer Invest. 2001;19:1–7
  21. Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg. 2002;124:270–277
  22. Meluch A, Greco A, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network Phase II Trial. Cancer J. 2003;9:251–260
  23. Goldberg M, Farma J, Lampert C, et al. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in respectable esophageal carcinoma: a phase I report. J Thorac Cardiovasc Surg. 2003;126:1168–1173
  24. Crosby TD, Brewster AE, Borley A, et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70–75
  25. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990;77:845–857
  26. Mukherjee S, Aston D, Minnett M, Brewster AE, Crosby TDL. The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers. Clin Oncol. 2003;15:115–120

PII: S0936-6555(05)00521-2

doi: 10.1016/j.clon.2005.12.009

Clinical Oncology
Volume 18, Issue 4 , Pages 338-344 , May 2006

Article Tools

* Image Usage & Resolution